Welcome to our dedicated page for Northwest Bio SEC filings (Ticker: NWBO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Northwest Biotherapeutics, Inc. (NWBO) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a reporting issuer whose common stock trades on the OTCQB. Through these filings, investors can review how Northwest Biotherapeutics describes its business of developing DCVax dendritic cell-based immunotherapies for solid tumor cancers, along with details on governance, financing, and capital structure.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company discusses its DCVax-L and DCVax-Direct programs, clinical trial status, manufacturing initiatives such as the Flaskworks system and the Sawston, UK facility, and risk factors relevant to its operations. These reports also provide information on research collaborations, in-licensed dendritic cell technology portfolios, and the acquisition of Advent BioServices Ltd.
Frequent current reports on Form 8-K highlight material events such as convertible note financings, commercial loan agreements, filing of shelf registration statements on Form S-3, settlement of litigation related to option awards, and the closing of the Advent acquisition. 8-K filings also document shareholder meeting outcomes, including votes on director elections, auditor ratification, increases in authorized common stock, and advisory votes on executive compensation.
Proxy statements on Schedule 14A (DEF 14A) provide further detail on corporate governance, board composition, compensation policies, and proposals presented to stockholders at annual meetings. Amendments to the certificate of incorporation, such as increases in authorized shares of common stock, are described in both proxy materials and related 8-K filings.
On Stock Titan, these filings are updated as they are released through EDGAR. AI-powered summaries help explain lengthy documents by highlighting core business descriptions, key financing terms, changes in share authorization, and other items that may affect NWBO’s capital structure and strategic flexibility. Users can also review filings related to registration statements and other corporate actions to build a more complete picture of Northwest Biotherapeutics’ regulatory and financial history.
Northwest Biotherapeutics (NWBO) closed its acquisition of Advent BioServices, which is now a wholly owned subsidiary. The deal transfers Advent’s fixed assets, including extensive cryostorage and related equipment, plus intellectual property and other intangibles, to NWBO.
No new shares are being issued. Instead, 19 million previously issued NWBO securities are reverting to the company, comprising 13.5 million shares and 5.5 million options. Cash consideration consists of a payment of £1.4 million and the net amount of accounts payable due to Advent for prior services. Payments will be made in installments over two years, with potential acceleration after regulatory approval of DCVax-L. Installments begin 90 days after the October closing, and the net accounts payable is determined as of the closing date.
Northwest Biotherapeutics (NWBO) reported that it filed a new Form S-3 shelf registration on October 23, 2025 to replace its existing shelf. Shelf registrations expire three years from effectiveness; the company’s current shelf became effective on October 25, 2022 and therefore expires on October 25, 2025. Filing the new shelf before expiration maintains an ongoing effective registration framework.
The company’s common stock trades on the OTCQB under the symbol NWBO.
Northwest Biotherapeutics filed a Form S-3 shelf registration to offer up to $250,000,000 of common stock, preferred stock, depositary shares, warrants, debt securities, share purchase contracts, share purchase units, and units, to be sold from time to time on terms set at each offering. Any specific terms, dealers or underwriters, and expected net proceeds will be detailed in prospectus supplements.
The company states it may use proceeds for general corporate purposes, including working capital, R&D, regulatory and clinical trial expenditures, capital spending, and potential technology acquisitions. NWBO’s common stock trades on the OTCQB under “NWBO”; the last reported sale price was $0.22 on October 20, 2025. As of October 20, 2025, there were 1,528,922,347 shares of common stock issued and outstanding. The public float was $327,321,282 based on 1,487,824,011 non‑affiliate shares at $0.22.
Northwest Biotherapeutics (NWBO) announced a settlement agreement, set out in a binding Term Sheet, to resolve Delaware Court of Chancery litigation over 2020 option awards to management and directors. Under the agreement, 17% of the challenged 2020 options will be cancelled, and the Company’s insurance carriers will pay $2.25 million to the Company.
The parties will use best efforts to complete definitive settlement documents within thirty days, and the settlement is subject to Court approval. The Lead Plaintiff intends to apply for an award of attorneys’ fees and expenses. Under the settlement, the $2.25 million payment is not to be used for any fee award; it is currently anticipated that any fee award will be paid separately by the Company’s insurers.